# Intensity Therapeutics (INTS) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/INTS
## Company Profile
- Ticker: INTS
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunotherapy, Oncology
## Stock Data
- Close: 4.16 USD
- Market cap: 11568069.600000001 USD
- Last updated: 2026-08-12
## Business Overview
### Intratumoral Cancer Therapy
Intensity Therapeutics develops medicines administered directly into tumors. Its approach is designed to kill injected tumor cells, expose tumor antigens, and stimulate a broader immune response.
### INT230-6
INT230-6 combines cytotoxic agents with a proprietary dispersion molecule intended to improve penetration throughout solid tumors. The candidate is being studied both before surgery and in advanced disease.
### Soft-Tissue Sarcoma
The Phase 3 INVINCIBLE-3 study evaluates INT230-6 as second- or third-line monotherapy against standard of care in soft-tissue sarcoma, with overall survival as the primary outcome.
### Triple-Negative Breast Cancer
The Phase 2 INVINCIBLE-4 study evaluates presurgical INT230-6 followed by standard immunochemotherapy against standard treatment alone in triple-negative breast cancer.
## Why The Stock Is Moving

Following the latest company update, “Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update”, INTS closed down 2.10% at $4.20 on Aug 11, 2026. The move occurred in the trading session associated with this earnings update.

## Future Catalysts

- Resumption of patient enrollment at a limited number of U.S. sites in the Phase 3 INVINCIBLE-3 study by the third quarter of 2026.
- Completion of enrollment in the Phase 2 INVINCIBLE-4 study by the end of 2027.

## Recent News
- 2026-08-11 11:30 EST — [Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/INTS/intensity-therapeutics-reports-second-quarter-2026-financial-results-and-provide-dc866819) — Source: Intensity Therapeutics
- 2026-08-04 12:00 EST — [Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026](https://biopharmsignal.com/news/INTS/intensity-therapeutics-to-announce-second-quarter-2026-financial-results-on-augu-543d453f) — Source: Intensity Therapeutics
- 2026-07-15 11:45 EST — [Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)](https://biopharmsignal.com/news/INTS/intensity-therapeutics-inc-restarts-patient-treatment-in-the-randomized-presurgi-51761e30) — Source: Intensity Therapeutics
- 2026-07-01 12:00 EST — [Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6](https://biopharmsignal.com/news/INTS/intensity-therapeutics-provides-mid-year-update-highlighting-late-stage-developm-93ef635a) — Source: Intensity Therapeutics
- 2026-05-14 12:00 EST — [Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award](https://biopharmsignal.com/news/INTS/intensity-therapeutics-recognized-with-ghp-magazine-s-2026-healthcare-and-pharmaceutical-award) — Source: Intensity Therapeutics